Does the Presence of Ductal Carcinoma in situ Affect Prognostic Outcomes After Neoadjuvant Therapy in Invasive Ductal Carcinoma of the Breast?
The presence of DCIS in IDC demonstrated less tumour aggressiveness than pure IDC. However, a survival benefit was only observed in patients with triple-negative IDC combined with DCIS after NAT. Furthermore, patients with IDC + DCIS have a higher risk of residual DCIS after NAT, and age <40 years and the luminal subtype are risk factors for residual DCIS after NAT in patients with IDC + DCIS.
Authors
- Yuhua Shi (ORCID: https://orcid.org/0000-0002-7413-4031)
- Zhen Huang (ORCID: https://orcid.org/0000-0003-4819-373X)
- 要子 伊藤 (ORCID: https://orcid.org/0000-0001-6877-5417)
- Suming Zhou (ORCID: https://orcid.org/0000-0002-6519-5094)
- Wei Xing (ORCID: https://orcid.org/0000-0003-2841-7206)
Institutions
- Peking University (CN)
- Hebei University of Chinese Medicine (CN)
- Peking University First Hospital (CN)
- Anyang Tumor Hospital (CN)
Publication Details
- Journal
- Clinical Oncology
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1016/j.clon.2025.103781
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Peking University First Hospital
- Peking University